Filing Flows › Keros Therapeutics (KROS) › Capital expenditures
Keros Therapeutics (KROS) capital expenditures by quarter
Keros Therapeutics' capital expenditures were $59K in Q3 2026 (third quarter 2026), -55% from Q3 2025. Over the last 3 quarters it ranged from $59K (Q3 2026) to $565K (Q1 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $59K | -55% | -55% |
| Q3 2025 | $132K | -77% | — |
| Q1 2025 | $565K | — | — |
Q3 2026 at a glance
Keros Therapeutics, Q3 2026: revenue $40.0M (+183% year over year), operating margin 32.0%, net earnings $14.2M, operating cash flow $3.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Keros Therapeutics' capital expenditures?
Keros Therapeutics' capital expenditures were $59K in Q3 2026 (third quarter 2026), -55% from Q3 2025.
How has Keros Therapeutics' capital expenditures changed?
Over the last 3 quarters it ranged from $59K (Q3 2026) to $565K (Q1 2025).